Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into adulthood. The standard first-line treatment option for AD patients is topical immunotherapy, which has proven broadly effective in managing symptoms. In topical-refractory patients, symptoms are commonly managed by systemic immunomodulators, which pose potentially serious side effects when administered over the long term. The launches of Pfizer’s Eucrisa (crisaborole), Sanofi / Regeneron’s Dupixent (dupilumab), two oral JAK inhibitors (AbbVie’s Rinvoq [upadacitinib], and Pfizer’s Cibinqo [abrocitinib]), one topical JAK inhibitor (Incyte’s Opzelura [ruxolitinib]), and LEO Pharma’s targeted biologic Adbry (tralokinumab) have greatly expanded the treatment options for AD patients across the severity spectrum. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug treatment trends in AD.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Sanofi / Regeneron, AbbVie, Incyte, LEO Pharma
Key drugs: Dupixent, Adbry, Cibinqo, Olumiant, Rinvoq, Opzelura, Eucrisa, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids, and calcineurin inhibitors
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.